Search Within

CTCR Scholars

  1. "Ahmet Dogan"
Formats
  1. Meeting Abstract (30)
  2. Journal Article (18)
  3. Research Letter (2)
  4. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (51)
  2. Department of Pathology and Laboratory Medicine (51)
  3. Department of Medicine (50)
  4. Hematologic Malignancies, Division of (50)
  5. Survivorship Research (49)
  6. Hematology-Oncology Fellows (46)

More Groups

People
  1. Ahmet Dogan (51)
  2. Gunjan Shah (24)
  3. Sergio Giralt (24)
  4. Malin Hultcrantz (23)
  5. Michael Scordo (23)
  6. Steven Horwitz (23)

More People

Years
  1. 2025 (2)
  2. 2024 (2)
  3. 2023 (5)
  4. 2022 (5)
  5. 2021 (13)
  6. 2020 (12)

More Years

Publications
  1. Blood (25)
  2. Hematological Oncology (3)
  3. Journal of Clinical Oncology (3)
  4. Blood Cancer Journal (2)
  5. Clinical Lymphoma, Myeloma and Leukemia (2)
  6. Leukemia and Lymphoma (2)

More Publications

Publishers
  1. American Society of Hematology (26)
  2. American Society of Clinical Oncology (4)
  3. Nature Publishing Group (4)
  4. Elsevier Inc. (3)
  5. Wiley Blackwell (3)
  6. Massachusetts Medical Society (2)

More Publishers

Results (51)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53
    Journal Article

    Perica, K.; Jain, N.; Scordo, M.; Patel, R.; Eren, O. C.; Patel, U.; Gundem, G.; Domenico, D.; Mitra, S.; Socci, N. D.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies
    Journal Article

    Krystel-Whittemore, M.; Petrova-Drus, K.; Ptashkin, R. N.; Ewalt, M. D.; Yao, J.; Liu, Y.; Zhu, M.; Benhamida, J.; Durham, B.; Kumar, J.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab-based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Cumulative incidence of myeloid neoplasms in patients with nodal T-follicular helper cell lymphoma
    Meeting Abstract

    Stuver, R.; Ganesan, N.; Dogan, A.; Epstein-Peterson, Z. D.; Ghione, P.; Johnson, W.; Lewis, N.; Moskowitz, A.; Shah, G. L.; Scordo, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Journal Article

    Maura, F.; Boyle, E. M.; Coffey, D.; Maclachlan, K.; Gagler, D.; Diamond, B.; Ghamlouch, H.; Blaney, P.; Ziccheddu, B.; Cirrincione, A.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Blaney, P.; Ziccheddu, B.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy
    Meeting Abstract

    Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save